Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
;
Dario
Greco
;
Carl
Blomqvist
;
Kristiina
Aittomäki
;
Sofia
Khan
;
Frans
Hogervorst
;
Senno
Verhoef
;
Paul DP
Pharoah
;
Alison M
Dunning
;
Mitul
Shah
;
+66 more...
Robert
Luben
;
Stig E
Bojesen
;
Børge G
Nordestgaard
;
Minouk
Schoemaker
;
Anthony
Swerdlow
;
Montserrat
García-Closas
;
Jonine
Figueroa
;
Thilo
Dörk
;
Natalia V
Bogdanova
;
Per
Hall
;
Jingmei
Li
;
Elza
Khusnutdinova
;
Marina
Bermisheva
;
Vessela
Kristensen
;
Anne-Lise
Borresen-Dale
;
NBCS Investigators
;
Julian
Peto
;
Isabel
Dos Santos Silva
;
Fergus J
Couch
;
Janet E
Olson
;
Peter
Hillemans
;
Tjoung-Won
Park-Simon
;
Hiltrud
Brauch
;
Ute
Hamann
;
Barbara
Burwinkel
;
Frederik
Marme
;
Alfons
Meindl
;
Rita K
Schmutzler
;
Angela
Cox
;
Simon S
Cross
;
Elinor J
Sawyer
;
Ian
Tomlinson
;
Diether
Lambrechts
;
Matthieu
Moisse
;
Annika
Lindblom
;
Sara
Margolin
;
Antoinette
Hollestelle
;
John WM
Martens
;
Peter A
Fasching
;
Matthias W
Beckmann
;
Irene L
Andrulis
;
Julia A
Knight
;
kConFab/AOCS Investigators
;
Hoda
Anton-Culver
;
Argyrios
Ziogas
;
Graham G
Giles
;
Roger L
Milne
;
Hermann
Brenner
;
Volker
Arndt
;
Arto
Mannermaa
;
Veli-Matti
Kosma
;
Jenny
Chang-Claude
;
Anja
Rudolph
;
Peter
Devilee
;
Caroline
Seynaeve
;
John L
Hopper
;
Melissa C
Southey
;
Esther M
John
;
Alice S
Whittemore
;
Manjeet K
Bolla
;
Qin
Wang
;
Kyriaki
Michailidou
;
Joe
Dennis
;
Douglas F
Easton
;
Marjanka K
Schmidt
;
Heli
Nevanlinna
;
(2016)
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Genetics in medicine, 19 (5).
pp. 599-603.
ISSN 1098-3600
DOI: 10.1038/gim.2016.147
PURPOSE: CHEK2*1100delC is a founder variant in European populations that confers a two- to threefold increased risk of breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated with CHEK2*1100delC is modified by other genetic factors in a multiplicative fashion. We have investigated this empirically using data from the Breast Cancer Association Consortium (BCAC). METHODS: Using genotype data from 39,139 (624 1100delC carriers) BC patients and 40,063 (224) healthy controls from 32 BCAC studies, we analyzed the combined risk effects of CHEK2*1100delC and 77 common variants in terms of a polygenic risk score (PRS) and pairwise interaction. RESULTS: The PRS conferred odds ratios (OR) of 1.59 (95% CI: 1.21-2.09) per standard deviation for BC for CHEK2*1100delC carriers and 1.58 (1.55-1.62) for noncarriers. No evidence of deviation from the multiplicative model was found. The OR for the highest quintile of the PRS was 2.03 (0.86-4.78) for CHEK2*1100delC carriers, placing them in the high risk category according to UK NICE guidelines. The OR for the lowest quintile was 0.52 (0.16-1.74), indicating a lifetime risk close to the population average. CONCLUSION: Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the common susceptibility variants. Furthermore, the PRS could identify carriers at a high lifetime risk for clinical actions.Genet Med advance online publication 06 October 2016.
-
picture_as_pdf - Genetic-modifiers-of-CHEK2-1100delC-associated-breast-cancer-risk.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0